EC nod for acquisition of Albany Molecular Research

The European Commission has approved, under the EU Merger Regulation, the acquisition of joint control of Albany Molecular Research (Nasdaq: AMRI) by Carlyle Partners and GTCR.

In June this year, AMRI, itself a serial acquirer of businesses over the past few years, signed a definitive agreement to be acquired by affiliates of the Carlyle Group and GTCR for $21.75 per share in cash, a deal valued at around $922 million. As of today, AMRI is trading at $21.74.

On June 29, the company announced the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with the proposed acquisition of AMRI.